Assistant Professor, Oncology, Mayo Medical School
Oncology
Dr. Randolph S. Marks, MD
|
|
Give Review
Dr. Randolph S. Marks works in the field of Oncology. He went to medical school at University of California Irvine School of Medicine. University of California Irvine School of Medicine has a rank of 45 in research and a 62 in primary care Randolph S. Marks has written publications. He has 53 publications published with PubMed. The lastest publication is: 'Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study.' He accepts all Medicare patients.
Publications
- Risk factors for incident venous thromboembolism in active Cancer patients: A population based case-control study.
- Risk of site-specific Cancer in incident venous thromboembolism: A population-based study.
- Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic Carcinomas.
- A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung Cancer: NCCTG trial N-0621.
- Wnt signaling pathway pharmacogenetics in non-small cell lung Cancer.
- Predictors of venous thromboembolism recurrence and bleeding among active Cancer patients: a population-based cohort study.
- Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials.
- NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm.
- Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small-Cell Lung Cancer:...
- Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
- Genome-wide association study of genetic predictors of overall survival for non-small cell lung Cancer in never smokers.
- Quality of Life and Symptom Burden among Long-Term Lung Cancer Survivors.
- Genetic Variants Associated with the Risk of Chronic Obstructive Pulmonary Disease with and without Lung Cancer.
- Effect of emphysema on lung Cancer risk in smokers: a computed tomography-based assessment.
- The association of active Cancer with venous thromboembolism location: a population-based study.
- Methylation markers for small cell lung Cancer in peripheral blood leukocyte DNA.
- Endpoints in phase II trials for advanced non-small cell lung Cancer.
- Prognostic factors differ by tumor stage for small cell lung cancer: a pooled Analysis of North Central Cancer Treatment Group trials.
- Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung Cancer risk.
- Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung Cancer.
- Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung Cancer (NCCTG 95-20-53).
- Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenoCarcinoma.
- A prognostic model for advanced stage nonsmall cell lung cancer. Pooled Analysis of North Central Cancer Treatment Group trials.
- Impact of pretreatment factors on adverse events: a pooled Analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials.
- Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an Analysis of 5018 hospital- and 712 population-based cases.
- Alpha1-antitrypsin and neutrophil elastase imbalance and lung Cancer risk.
- Clinical features of 5,628 primary lung Cancer patients: experience at Mayo Clinic from 1997 to 2003.
- Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung Cancer.
- Gender differences in non-small-cell lung cancer survival: an Analysis of 4,618 patients diagnosed between 1997 and 2002.
- Immunomodulatory treatment trial for paraneoplastic neurological Disorders.
- A phase II study of the dolastatin 15 Analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.
- A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced Cancer.
- Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung Cancers.
- Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung Carcinoma: a phase II ...
- Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung Cancer.
- Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung Cancer.
- Screening for lung Cancer with low-dose spiral computed tomography.
- A quality-adjusted reAnalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell...
- Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal Tumors ...
- Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung Cancer.
- Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung Cancer.
- Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung Cancer.
- Prolonged survival in patients with resected non-small cell lung Cancer and single-level N2 disease.
- Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastom...
- Do patients with schizophrenia receive state-of-the-art lung Cancer therapy? A brief report.
- Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung Cancer (NSCLC) after completion of initial therapy...
- Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage ...
- Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung Cancer (NSCLC) does not increase the expe...
- Prognostic factors for limited-stage small cell lung Cancer: a study of 284 patients.
- Genetic variants and risk of lung Cancer in never smokers: a genome-wide association study.
- Ulcerative colitis, infliximab, and hepatic epithelioid hemangioendothelioma: who is to blame? Case Report.
- Genetic determinants of lung Cancer short-term survival: the role of glutathione-related genes.
Schools
University Of California Irvine College Of Medicine
Mayo Clinic Rochester
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Mayo School of Graduate Medical Education -
University of California Irvine School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1952389611 | |
| NPPES Provider LastName | MARKS | |
| NPPES Provider FirstName | RANDOLPH | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 363.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 44.0 | |
| Percent Opioid Claims | 12.12 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952389611 |
| Last Name Of The Provider | MARKS |
| First Name Of The Provider | RANDOLPH |
| View All |
Similar Doctors
|
|
Dr. Keith C. Bible, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian A. Costello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prashant Kapoor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joleen M. Hubbard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn S. Harman, MD |
|
|
Dr. Denis M. Bonin, MD |
|
|
Dr. Matthew P. Goetz, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Robert C. Miller, MD |
|
|
Dr. Rakhee R. Vaidya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minetta Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ron S. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Andrew C. Hendrickson
This Doctor is OpenDoctor Recommended.
|